Cognigenics

Cognigenics is a health and wellness startup that focuses on developing RNA-based gene therapies for addressing memory loss, cognitive decline, anxiety, and other neurocognitive and neuropsychiatric disorders. With a slogan of "Shaping the Future of Genetic Medicines for Mental Health and Neurocognitive Disorders," the company aims to target neuronal receptors in the brain associated with CNS disorders. Since its establishment in 2019, Cognigenics has made significant strides in its field.

The company recently secured a $1.59M Seed Round investment on 16 August 2022, with the investment coming from Lionheart Ventures. This funding is expected to further bolster Cognigenics' efforts in pioneering innovative treatments for neurocognitive and neuropsychiatric conditions.

With its focus on RNA-based therapies and intranasal delivery platforms, Cognigenics stands at the forefront of developing potential solutions for neurological disorders. Situated in the United States, the company's commitment to advancing the field of genetic medicines for mental health signifies its potential to make a significant impact in the industry.